GSK

GSK announces positive results from DREAMM-8 phase III trial for Blenrep

GSK plc announces positive results from DREAMM-8 trial evaluating Blenrep in combination with PomDex for multiple myeloma treatment. Exciting news for patients and potential treatment advancements...

GSK ViiV Healthcare reports Positive Findings for ultra long-acting HIV treatment Cabotegravir

GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...

GSK settles another Zantac litigation case

GSK plc has reached a confidential settlement with Boyd/Steenvoord in a California state court case, avoiding a trial set for April 2, 2024...

ViiV Healthcare announces Superiority of long-acting HIV Therapy over daily oral treatment

ViiV Healthcare announces promising results from LATITUDE phase III trial, showing long-acting HIV treatment Cabenuva's superiority over daily oral therapy...

GSK completes acquisition of Aiolos Bio, expanding respiratory biologics portfolio

GSK plc has completed the acquisition of Aiolos Bio, expanding its respiratory biologics portfolio with AIO-001, a potential treatment for asthma patients with low T2 inflammation. The acquisition includes an upfront payment of $1 billion and milestone payments...

GSK receives FDA fast track designation for Bepirovirsen for Chronic Hepatitis B

GSK plc has received Fast Track designation from the FDA for bepirovirsen, an investigational drug for chronic hepatitis B treatment. This designation highlights the need for effective medications to address this serious condition...

GSK’s RSV vaccine for adults 50-59 at increased risk accepted by FDA for Priority Review

GSK plc's application to extend its RSV vaccine indication to adults aged 50-59 at risk has been accepted by the FDA for priority review. If approved, it would be the first vaccine for this population. The application is supported by positive phase III trial results...

GSK reaches confidential settlement with David Browne in Zantac case

GSK has reached a confidential settlement with David Browne, resolving a California state court case. The company will continue to defend itself in other Zantac cases...

GSK plc delivers Strong Sales and Earnings Growth in 2023

GSK plc announces strong financial results, with sales and profits driven by broad-based performance and COVID-19 vaccine sales...
Search

Funds

GSK

GSK announces positive results from DREAMM-8 phase III trial for Blenrep

GSK plc announces positive results from DREAMM-8 trial evaluating Blenrep in combination with PomDex for multiple myeloma treatment. Exciting news for patients and potential treatment advancements...

GSK ViiV Healthcare reports Positive Findings for ultra long-acting HIV treatment Cabotegravir

GSK plc's ViiV Healthcare announces positive findings from a phase I study on cabotegravir ultra long-acting for HIV treatment. Exciting progress in long-acting medication development...

GSK settles another Zantac litigation case

GSK plc has reached a confidential settlement with Boyd/Steenvoord in a California state court case, avoiding a trial set for April 2, 2024...

ViiV Healthcare announces Superiority of long-acting HIV Therapy over daily oral treatment

ViiV Healthcare announces promising results from LATITUDE phase III trial, showing long-acting HIV treatment Cabenuva's superiority over daily oral therapy...

GSK completes acquisition of Aiolos Bio, expanding respiratory biologics portfolio

GSK plc has completed the acquisition of Aiolos Bio, expanding its respiratory biologics portfolio with AIO-001, a potential treatment for asthma patients with low T2 inflammation. The acquisition includes an upfront payment of $1 billion and milestone payments...

GSK receives FDA fast track designation for Bepirovirsen for Chronic Hepatitis B

GSK plc has received Fast Track designation from the FDA for bepirovirsen, an investigational drug for chronic hepatitis B treatment. This designation highlights the need for effective medications to address this serious condition...

GSK’s RSV vaccine for adults 50-59 at increased risk accepted by FDA for Priority Review

GSK plc's application to extend its RSV vaccine indication to adults aged 50-59 at risk has been accepted by the FDA for priority review. If approved, it would be the first vaccine for this population. The application is supported by positive phase III trial results...

GSK reaches confidential settlement with David Browne in Zantac case

GSK has reached a confidential settlement with David Browne, resolving a California state court case. The company will continue to defend itself in other Zantac cases...

GSK plc delivers Strong Sales and Earnings Growth in 2023

GSK plc announces strong financial results, with sales and profits driven by broad-based performance and COVID-19 vaccine sales...
Search

Funds

GSK

FTSE 100

Funds